ECP 2023 Final Programme

Monday, 11 Sept 187 ECP 2023 Dublin 002 13:03–13:05 A Patient’s Cancer Journey Caterina Marchiò, Italy 003 13:05–13:40 Value of CGP in Routine Clinical Practice Csaba Bödör, Hungary 004 13:40–14:15 Importance of Early Testing and Treatment for Optimal Patient Care Nicola Normanno, Italy Robert Haddad, USA 005 14:15–14:25 Strategies to Implement CGP Routinely, Including Rare Biomarkers (All Faculty) Caterina Marchiò, Italy 006 14:25–14:30 Closing Remarks Caterina Marchiò, Italy LS-09 Industry Symposium 13:00–14:30 Liffey B Decoding Non-Small Cell Lung Cancer: Insights and Approaches for Precision Diagnosis (Janssen & Roche) Chair: Umberto Malapelle, Italy 001 NSCLC, the frontrunner in precision medicine Dearbhaile Collins, Ireland 002 Molecular tumour board goes live: Multi- disciplinary discussion of NSCLC patient cases (All Faculty) Umberto Malapelle, Italy 003 Paving the Way: Genomic Testing Access & Future Developments (Panel discussion–All Faculty) Umberto Malapelle, Italy Léon van Kempen, Belgium Ana Peixoto, Portugal Nicola Fusco, Italy LS-10 Industry Symposium 13:00–14:30 Liffey Hall 2 Improving treatment outcomes in gynae- cological cancers: The importance of early biomarker testing (GSK) Chair: Frédérique Penault-Llorca, France 001 13:00–13:10 Introduction to early biomarker testing in gynaecological cancers Frédérique Penault-Llorca, France 002 13:10–13:30 Beyond TCGA classification: How biomarker testing is evolving in endometrial cancer Glenn McCluggage, United Kingdom 003 13:30–13:50 How biomarker testing translates to clinical practice: Endometrial cancer (Panel discussion–All Faculty) Angela George, United Kingdom 004 13:50–14:10 The importance of testing early: Using biomarkers to guide therapeutic decisions in ovarian cancer Frédérique Penault-Llorca, France 005 14:10–14:30 How biomarker testing translates to clinical practice: Ovarian cancer (Panel discussion–All Faculty) Angela George, United Kingdom Industry Symposia